TRINETRA › Sectors › Healthcare
Nephrocare Health Services Limited (NEPHROPLUS) — share price, P/E and fundamentals
Nephrocare Health Services Limited (NSE: NEPHROPLUS) closed at ₹609.90 on 30 Oct 2026, against a 52-week range of ₹446.00 – ₹781.50.
In the quarter ended 30 Jun 2026 (consolidated, filed 11 Aug 2026) it reported revenue of ₹282 cr and net profit of ₹32 cr, a 11.4% net margin.
No trailing P/E is published: only 3 filed quarters available — a trailing twelve months needs 4.
From the balance sheet dated 31 Mar 2026: return on equity 11.5%, ROCE 16.0%, debt-to-equity 0.07.
Against 65 Healthcare peers on NSE: Net margin higher than 33% of 63 sector peers; PBT margin higher than 36% of 63 sector peers; ROE higher than 33% of 63 sector peers.
Key figures
| Last close | ₹609.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -14.0% / +14.3% / — |
| 52-week low – high | ₹446.00 – ₹781.50 |
| Market capitalisation | ₹6,120 cr |
| Quarter revenue | ₹282 cr |
| Quarter net profit | ₹32 cr |
| Net margin | 11.4% |
| Return on equity | 11.5% |
| ROCE | 16.0% |
| Debt / equity | 0.07 |
| Current ratio | 2.80 |
| Free cash flow | ₹114 cr |
| Average daily turnover (50 days) | ₹12.4 cr |
Against Healthcare peers
| Metric | NEPHROPLUS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.35 | 12.89 | 33 |
| PBT margin | 15.83 | 17.68 | 37 |
| ROE | 11.46 | 13.87 | 33 |
| ROCE | 15.98 | 17.26 | 43 |
| Debt / equity | 0.07 | 0.11 | 44 |
| Cash conversion | 3.03 | 1.25 | 93 |
Questions
What were Nephrocare Health Services Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Nephrocare Health Services Limited reported revenue of ₹282 cr and net profit of ₹32 cr (consolidated), filed with the exchange on 11 Aug 2026.
What is Nephrocare Health Services Limited's ROE?
Return on equity is 11.5% based on the balance sheet dated 31 Mar 2026.
Does Nephrocare Health Services Limited have debt?
Debt-to-equity is 0.07 on the balance sheet dated 31 Mar 2026.
What is NEPHROPLUS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, NEPHROPLUS traded between ₹446.00 and ₹781.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.